Form 4: Kymera Therapeutics COO Sells Shares to Cover Tax Obligations

Kymera Therapeutics, Inc.'s Chief Operating Officer, Jeremy G. Chadwick, sold 2,575 shares of common stock on May 23, 2025, to satisfy tax withholding obligations related to restricted stock unit vesting.

Summary

• Jeremy G. Chadwick, Chief Operating Officer of Kymera Therapeutics, Inc. (KYMR), reported a sale of common stock.
• The transaction occurred on May 23, 2025.
• A total of 2,575 shares of common stock were disposed of.
• The shares were sold at a weighted average price of $29.2954 per share, with individual transactions ranging from $29.18 to $29.52.
• The sale was non-discretionary and executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mr. Chadwick beneficially owns 66,420 shares, which includes 1,195 shares and shares acquired under the Registrant's employee stock purchase plan.

Sentiment

Score: 5

Explanation: The transaction reported is a routine, non-discretionary sale of shares by an officer to cover tax withholding obligations related to the vesting of restricted stock units, which is a common occurrence and does not reflect a change in management's confidence or company performance.

Future Outlook

N/A

Management Comments

• Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person.

Industry Context

N/A

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in company fundamentals or management's outlook.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Form 4, Insider Transaction, Stock Sale, Jeremy G. Chadwick, Chief Operating Officer, Restricted Stock Units, Tax Withholding